Christian Gisselbrecht
Christian Gisselbrecht is an expert in Hematology at Hôpital Saint-Louis (France). As of September 2026, ScienceLeadR ranks Christian Gisselbrecht in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Christian Gisselbrecht has authored 484 publications, the most recent in 2026, and is an investigator in 11 clinical trials. SLR score: 1,603 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1983 - 2026
Number : 484
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Beyond maximum grade: key regulatory considerations in adverse event reporting. PMID 42660133 — drug-related side effects and adverse reactions, therapeutics, hematologic diseases | Lancet Haematol | 2026 | 0 |
| Reduce bureaucracy in clinical trials now. PMID 41491100 — molecular biology | Nat Med Top journal | 2026 | 0 |
| Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant? PMID 36120952 — cells, transplantation, autologous, microscopy, electron, scanning transmission, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, stem cells, transplants, therapeutics, b-lymphocytes | Br J Haematol | 2022 | 1 |
| Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. PMID 35483398 — hematologic diseases, drug-related side effects and adverse reactions, therapeutics, neoplasms | Lancet Haematol | 2022 | 17 |
| EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. PMID 34213061 — therapeutics, disease-free survival, european union, multiple myeloma, dexamethasone, progression-free survival | Oncologist | 2021 | 3 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
LeadR Networks
Main global connection map